• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Government Agencies / North American / The United States / ACIP / Evidence Flu Vaccines Are Needless and Useless

Evidence Flu Vaccines Are Needless and Useless

January 21, 2011 By admin Leave a Comment

Posted by:  Joe Sheffler

02 November 2010

The Advisory Committee on Immunization Practice (ACIP) met in Atlanta, GA, on October 27-28, 2010. Complete minutes of the meeting will be published on the CDC National Center for Immunization and Respiratory Diseases (NCIRD) website (www.cdc.gov/vaccines/recs/acip).

Meningococcal vaccine

The first discussion was on meningococcal vaccine in patients with increased risk of disease, particularly patients with complement deficiency, HIV, or asplenia. Evidence was presented that the recommended one-dose schedule is inadequate to provide protection in these patients. A two-dose vaccination series, 2 months apart, was highly immunogenic. The committee voted and approved this schedule change.

Evidence also was presented that a single dose of meningococcal vaccine at 11 to 12 years of age did not provide adequate protection through college. Studies show the vaccine does not protect for more than 5 years. Cost-effectiveness data for vaccination of adolescents with the current recommendation of a single dose at age 11 to 12 years is the least cost-effective model; a single dose at age 15 years would prevent the greatest number of cases per dose given, and a dose at 11 years with a booster at 16 years would prevent the most number of cases. Since vaccination of adolescents began, the total number of cases in those 11 to 22 years of age during a 4-year period has decreased from 214 (2000-04) to 141 (2005-09) cases-a decrease of 34%. Vaccine effectiveness has been estimated at 78%. In summary, the low incidence of disease and low vaccination coverage have limited the power of these studies. The working group also recognized that this age group presents programmatic difficulties as a result of low number of provider visits and high vaccine cost. The committee, following a great deal of discussion and public comment, voted to keep the first dose at 11 to 12 years of age and to add a booster dose at age 16 or 5 years after the previous dose if they received the vaccine at an older age. Of note, the vote was close: 6 members were for and 5 were against the change.

Hepatitis B vaccine

Hepatitis B vaccination in high-risk adults was discussed. Vaccination coverage is improving but is still below desired levels. It was reported that 75% of health care workers have received only one dose of hepatitis B vaccine and 68% received all three doses. The ACIP working group on hepatitis B vaccination reviewed the incidence of hepatitis in people with diabetes (which is higher than the general population) and came to several conclusions: (1) infection control practices are not sufficient to prevent the disease, (2) seroprevalence of hepatitis B is increased in diabetes, and (3) vaccination is likely to substantially reduce the risk in people with diabetes. One area of concern is the practice of assisted monitoring of blood glucose (AMBG). The settings in which AMBG is performed include nursing homes, assisted-living facilities, hospitals, clinics, senior centers, health fairs, correctional facilities, schools, camps, and shelters. Risk of exposure increases at settings where shared-use monitors and lancet devices are used. Not changing gloves between patients also increases the risk. The working group will continue to discuss the issue surrounding hepatitis B and diabetes. Future discussions will include declining seroprotection and cost effectiveness in older patients, age criteria for vaccination, whether all patients with diabetes should be vaccinated or only certain identified groups, and if titers should be drawn following vaccination.

Pertussis

The incidence of pertussis is increasing. In addition, several outbreaks have occurred around the United States. The California Department of Health received reports of increase in pertussis cases in March 2010. The health department immediately began efforts to increase vaccination rates with tetanus-diphtheria-acellular pertussis (Tdap) vaccine. Intensive education efforts regarding diagnosis, treatment, recommendations for vaccination, and cocooning were put in place to meet their goal of protecting infants. Barriers started to arise concerning availability of Tdap, confusing guidelines about minimal intervals between tetanus-diphtheria (Td) and Tdap, licensing of Tdap for children aged 7 to 9 years, and emergency departments not following Tdap recommendations for wound management. Initially, free vaccine was offered to postpartum women and other infant contacts. In July, recommendations were expanded beyond ACIP recommendations to include women of childbearing age (including during pregnancy), all persons who have contact with infants, persons older than 64 years, underimmunized children aged 7 to 9 years, and wound management (which was an existing ACIP recommendation). The minimal interval between Td and Tdap was eliminated. From March to mid-October, a total of 6,978 cases and 10 infant deaths have been reported. The health department discovered during its investigations that a large pool of susceptible persons in need of vaccination exists. Although most of the young children were immunized, mandates for middle-school vaccination were implemented in September 2010. The investigation is continuing.

Read the entire article here.

Related

Filed Under: ACIP, United States, Vaccines Tagged With: ACIP, hepatitis B vaccine, meningococcal vaccine, pertussis, safety

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

AAVP: Outraged by Mexican Girl’s Death After HPV Vaccine

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

HPV Vaccine: Miracle or menace?

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2022 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in